Get In Touch
Have any questions or comments about the content you see on this page?
December 7, 2020
When we first published the Alnylam Patient Access Philosophy in 2017, we had no way of anticipating the extraordinary developments of 2020 brought on by the global COVID-19 pandemic and how significantly they’d impact patients and their access to medicines and healthcare. As we publish our second annual readout on our progress – our 2020 Patient Access Philosophy Report [Link to PDF], the way we think about and approach patient access seems more urgent than ever.
At Alnylam, we have a shared philosophy when it comes to patient access: our innovative therapies must get to those who may benefit from them. This philosophy of putting the patient first isn’t just a belief common among our leadership and employees, it’s a statement of intent and a specific set of actions that we’ve undertaken as a company.
Our Patient Access Philosophy recognizes that Alnylam has a critical role to play beyond our science and the development of drugs, which is that a biopharmaceutical company’s actions to help ensure access must be bigger than just those related to insurance coverage and reimbursement.
Beyond discovery and development of our medicines, our job is to listen to patients, payers and providers, and then to respond thoughtfully, collaboratively and transparently with actions and programs to help as many people as possible who need access to these treatments and associated care. Especially in times like these, access is about flexibility in points of care as much as it is about addressing financial burdens and coverage. - John Maraganore, Ph.D, Alnylam CEO
We know that to make our commitment to access more than mere words, we must continually track and assess our progress and regularly report our findings, and so we have defined a series of quantifiable and transparent metrics that allow us to measure our progress against three key guiding beliefs: patients come first, innovation is key in everything we do and accountability is a must. These metrics form the basis of our Patient Access Philosophy Report.
The report highlights Alnylam’s achievements in the U.S. as well as our expansion into other markets like CEMEA (Central Europe, Middle East and Africa). It also addresses the progress we have made in supporting access to our RNAi therapeutics and how Alnylam has addressed needs related to site of care, COVID-19, evolving local policies and advocacy, and various other matters.
Highlights from the 2020 Patient Access Philosophy Report:
Helping patients from clinical development through commercialization...
Improving diagnosis and providing education...
Breaking down barriers to expedite access to treatment...
Delivering value to patients and payers...
We hope that you will take the time to read the 2020 Patient Access Philosophy Report and learn how we are doing our part to improve access worldwide.
The following content may not be associated with Alnylam Pharmaceuticals.
Links to all outside sites are provided as a reference for our visitors.
Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.Proceed to Site